Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
Open Access
- 17 January 2013
- journal article
- case report
- Published by Wiley in Case Reports in Transplantation
- Vol. 2013, 1-3
Abstract
Tuberous sclerosis is rarely associated with autosomal dominant polycystic kidney disease in the so-called tuberous sclerosis complex. This association leads to an increased frequency of end-stage renal disease. We present a patient suffering from both syndromes, who received a renal graft and anticalcineurinic drugs as immunosuppressive agents. Progressive titration of the drug was necessary in order to attain the effective doses due to the enzymatic induction caused by concomitant treatment with antiepileptic drugs. These high doses resulted in nephrotoxicity. Immunosuppressor treatment was switched to rapamycin, whereby an improvement in renal function and other signs of tuberous sclerosis and polycystic kidney disease was observed. This case report highlights both the efficacy and safety of rapamycin as an immunosuppressor treatment and its capacity for controlling other symptoms of these genetic-related disorders.Keywords
This publication has 5 references indexed in Scilit:
- The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspectiveChild's Nervous System, 2011
- Tuberous sclerosis complex: tumors and tumorigenesisInternational Journal of Dermatology, 2010
- The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantationKidney International, 2010
- Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunityTransplant International, 2010
- Rapamycin as a Therapy of Choice After Renal Transplantation in a Patient With Tuberous Sclerosis ComplexTransplantation Proceedings, 2009